Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_assertion type Assertion NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_head.
- NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_assertion description "[Imatinib was the first BCR-ABL1 tyrosine kinase inhibitor (TKI) developed for the treatment of patients with chronic myeloid leukemia (CML); subsequently, the introduction of more potent BCR-ABL1 TKIs has raised expectations regarding the speed and depth of response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_provenance.
- NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_assertion evidence source_evidence_literature NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_provenance.
- NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_assertion SIO_000772 25410137 NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_provenance.
- NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_assertion wasDerivedFrom befree-2016 NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_provenance.
- NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_assertion wasGeneratedBy ECO_0000203 NP1238632.RAjfSusU1ztF95y5CVfP9qNBZhJHoDgQVLCiRlNso3AoM130_provenance.